Cometriq(cabozantinib)
Cabometyx, Cometriq (cabozantinib) is a small molecule pharmaceutical. Cabozantinib was first approved as Cometriq on 2012-11-29. It is used to treat renal cell carcinoma in the USA. It has been approved in Europe to treat hepatocellular carcinoma, renal cell carcinoma, and thyroid neoplasms. The pharmaceutical is active against hepatocyte growth factor receptor and vascular endothelial growth factor receptor 2. In addition, it is known to target proto-oncogene tyrosine-protein kinase receptor Ret.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Cabometyx, Cometriq
Drug Products
FDA
EMA
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| renal cell carcinoma | EFO_0000376 | D002292 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
CABOZANTINIB S-MALATE, CABOMETYX, EXELIXIS INC | |||
| 2028-09-17 | ODE-375 | ||
| 2026-01-14 | ODE-227 | ||
| 2024-09-17 | I-873 | ||
| 2024-01-22 | I-854 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Cabozantinib S-Malate, Cabometyx, Exelixis Inc | |||
| 9724342 | 2033-07-09 | DP | |
| 11298349 | 2032-02-10 | DP | |
| 10034873 | 2031-07-18 | U-2488 | |
| 10039757 | 2031-07-18 | U-1480 | |
| 8877776 | 2030-10-08 | DS, DP | U-1617, U-3225 |
| 11091439 | 2030-01-15 | DP | |
| 11091440 | 2030-01-15 | DP | |
| 11098015 | 2030-01-15 | U-1220, U-1480, U-1617, U-2488, U-3225 | |
| 7579473 | 2026-08-14 | DS, DP | |
| 8497284 | 2024-09-24 | U-1220, U-1480, U-2488 | |
| Cabozantinib S-Malate, Cometriq, Exelixis | |||
| 9717720 | 2032-02-10 | DP | |
HCPCS
No data
Clinical
Clinical Trials
286 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal cell carcinoma | D002292 | EFO_0000376 | — | — | 2 | — | 1 | 13 | 16 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thyroid neoplasms | D013964 | EFO_0003841 | — | — | 1 | 1 | — | — | 2 |
| Papillary thyroid cancer | D000077273 | — | — | — | — | 1 | — | — | 1 |
| Follicular adenocarcinoma | D018263 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | — | 3 | — | — | 9 | 12 |
| Neoplasms | D009369 | — | C80 | — | 6 | — | — | — | 6 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | — | 2 | — | — | — | 2 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | 2 | — | — | — | 2 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 2 | — | — | — | 2 |
| Osteosarcoma | D012516 | — | — | — | 2 | — | — | — | 2 |
| Pheochromocytoma | D010673 | — | — | — | 1 | — | — | — | 1 |
| Adenocarcinoma | D000230 | — | — | — | 1 | — | — | — | 1 |
| Anaplastic thyroid carcinoma | D065646 | — | — | — | 1 | — | — | — | 1 |
| Paraganglioma | D010235 | — | — | — | 1 | — | — | — | 1 |
Show 14 more
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cabozantinib |
| INN | cabozantinib |
| Description | Cabozantinib is a dicarboxylic acid diamide that is N-phenyl-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in which the hydrogen at position 4 on the phenyl ring is substituted by a (6,7-dimethoxyquinolin-4-yl)oxy group. A multi-tyrosine kinase inhibitor, used (as its malate salt) for the treatment of progressive, metastatic, medullary thyroid cancer. It has a role as a tyrosine kinase inhibitor and an antineoplastic agent. It is a member of quinolines, an organofluorine compound, an aromatic ether and a dicarboxylic acid diamide. |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC |
Identifiers
| PDB | — |
| CAS-ID | 849217-68-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2105717 |
| ChEBI ID | 72317 |
| PubChem CID | 25102847 |
| DrugBank | DB08875 |
| UNII ID | 1C39JW444G (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
RET
RET
Organism
Homo sapiens
Gene name
RET
Gene synonyms
CDHF12, CDHR16, PTC, RET51
NCBI Gene ID
Protein name
proto-oncogene tyrosine-protein kinase receptor Ret
Protein synonyms
Cadherin family member 12, cadherin-related family member 16, Proto-oncogene c-Ret, rearranged during transfection, ret proto-oncogene (multiple endocrine neoplasia and medullary thyroid carcinoma 1, Hirschsprung disease), RET receptor tyrosine kinase
Uniprot ID
Mouse ortholog
Ret (19713)
proto-oncogene tyrosine-protein kinase receptor Ret (P35546)
Variants
No data
Financial
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 13,153 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
44,187 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use